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Effects of Statins on Endothelial Progenitor Cell 
Proliferation from Peripheral Blood of Stable 
  Coronary Artery Disease Patient
Feranti Meuthia, Yudi Her Oktaviono, Djoko Soemantri
Background: Atherosclerotic lesions develop as the result of an inflammatory process 
initiated by endothelial damage. Endothelial progrenitor cells (EPCs), which is derived 
from bone marrow, participate in endothelial repair and new vessel growth. Cardio-
vascular pharmacotherapies have been shown to improve overall numbers and function 
of EPCs in patients with cardiovascular risk and cardiovascular disease. Studies have 
reported that statins exert beneficial effects on EPCs by enhancing EPC proliferation 
and differentiation. Thus, we require a research to analyze the effects of three different 
statins on EPC proliferation. The objective of this study is to analyze the effect of statins 
on EPC proliferation from peripheral blood of stable coronary artery disease patient.
Methods: This is an in vitro true experimental post-test only control group design. The 
mononuclear cells (MNCs) were isolated from peripheral blood of stable coronary artery 
disease patient and were cultured in CFU-Hill medium for three days. Then samples 
were put into four groups, simvastatin experiment group, atorvastatin experiment group, 
rosuvastatin experiment group and control group. Each experiment group was divided 
into three subgroups with different doses, 0.1 µmol/L, 0.5 µmol/L, and 2.5 µmol/L then 
incubated for 48 hours. EPC proliferation was evaluated afterwards with MTT cell 
proliferation assay. Immunocytochemistry method was performed for EPC identifica-
tion to evaluate expression of CD34+. CFU-Hills were observed to confirm functional 
characteristics of EPC. Data were analyzed by independent T-test and ANOVA. 
Results: MTT cell proliferation assay showed a significant increase of EPC prolifera-
tion in simvastatin, atorvastatin, and rosuvastatin groups compared with control group 
(0.237±0.007, 0.248±0.01, 0.231±0.008 vs 0.17±0.008, p<0.05). It also revealed 
significant difference in EPC proliferation between each experiment groups, which 
atorvastatin showed the highest effect. EPC proliferation in atorvastatin is higher than 
simvastatin group (0.248±0.01 vs. 0.237±0.007, p<0.05), and simvastatin is also higher 
than rosuvastatin group (0.237±0.007 vs. 0.231±0.008, p<0.05). CFU-Hill counts 
demonstrated highest number in rosuvastatin group, followed by atorvastatin, and 
simvastatin. Immunocytochemistry showed positive expression of CD34.  
Conclusion: Statins increase EPC proliferation from peripheral blood of stable 
coronary artery disease patient. Atorvastatin showed the highest EPC proliferation, 
followed by simvastatin, and rosuvastatin. Each statins increased EPC proliferation 
dose-dependently.   
(J Kardiol Indones. 2017;38:6-12)
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Latar Belakang: Lesi atherosklerotik merupakan akibat dari proses inflamasi yang diawali oleh kerusakan endotel. Endothelial progenitor cell (EPC), 
yang berasal dari sumsum tulang, berpartisipasi dalam perbaikan endotel dan pertumbuhan pembuluh darah baru. Farmakoterapi kardiovaskular 
telah dibuktikan dapat memperbaiki jumlah dan fungsi EPC pada penderita dengan risiko kardiovaskular dan penyakit kardiovaskular. Banyak 
studi melaporkan bahwa statin memiliki efek yang menguntungkan terhadap EPC yaitu dengan meningkatkan proliferasi dan diferensiasi. 
Oleh karena itu, kami melakukan penelitian untuk menganalisis efek tiga statin yang berbeda terhadap proliferasi EPC. Tujuan penelitian ini 
adalah untuk menganalisis efek pemberian statin terhadap proliferasi EPC pada darah tepi penderita penyakit jantung koroner stabil.
Metode: Penelitian ini kami lakukan secara in vitro true experimental post-test only control group design. Sel mononuklear diisolasi dari darah tepi 
penderita penyakit jantung koroner stabil dan kultur dilakukan dalam medium CFU-Hill selama tiga hari. Sampel kemudian dibagi menjadi 
empat kelompok, yaitu kelompok simvastatin, atorvastatin, rosuvastatin dan kelompok kontrol. Tiap kelompok yang diberi perlakuan tersebut 
dibagi lagi menjadi tiga subkelompok dengan dosis yang berbeda, yaitu 0,1 µmol/L, 0,5 µmol/L, dan 2,5 µmol/L kemudian diinkubasi selama 
48 jam. Proliferasi EPC dievaluasi setelahnya dengan MTT cell proliferation assay. Metode imunositokimia dilakukan untuk identifikasi EPC 
dengan mengevaluasi ekspresi CD34+. Pemeriksaan dan penghitungan CFU-Hill dilakukan untuk mengonfirmasi karakteristik fungsional 
EPC. Data dianalisis dengan uji T independen dan ANOVA.
Hasil: MTT cell proliferation assay menunjukkan peningkatan bermakna terhadap proliferasi EPC pada kelompok simvastatin, atorvastatin, 
dan rosuvastatin dibandingkan dengn kelompok kontrol (0,237±0,007, 0,248±0,01, 0,231±0,008 vs. 0,17±0,008, p<0,05). Proliferasi EPC 
juga berbeda antar-kelompok statin, dengan efek tertinggi didapatkan pada kelompok atorvastatin. Proliferasi EPC pada kelompok atorvastatin 
lebih tinggi daripada kelompok simvastatin (0,248±0,01 vs. 0,237±0,007, p<0,05), dan simvastatin lebih tinggi daripada kelompok rosuvas-
tatin (0,237±0,007 vs. 0,231±0,008, p<0,05). Penghitungan CFU-Hill memperlihatkan jumlah tertinggi pada kelompok rosuvastatin, diikuti 
atorvastatin, dan simvastatin. Pemeriksaan imunositokimia menunjukkan ekspresi positif terhadap CD34. 
Kesimpulan: Statin meningkatkan proliferasi EPC pada darah tepi penderita penyakit jantung koroner stabil. Efek tertinggi tampak pada 
kelompok atorvastatin, diikuti kelompok simvastatin, dan rosuvastatin. Tiap statin meningkatkan proliferasi dengan bergantung dosis (dose-
dependent). 
(J Kardiol Indones. 2017;38:6-12)
Kata kunci: proliferasi EPC, simvastatin, atorvastatin, rosuvastatin
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Introduction
Cardiovascular disease (CVD) remains the biggest cause of deaths worldwide. It is responsible for over 17 million deaths per year.1 The underlying disease process in 
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tients before peripheral blood sampling. The protocol 
was approved by local ethics committee (320/Panke.
KKE/IV/2016).
Isolation and culture of EPCs
Forty ml of blood was diluted with phosphate buffered 
saline (PBS) containing 2% of fetal bovine serum 
(FBS). It was then centrifuged on Ficoll-Histopaque 
density gradients and interface mononuclear cells 
(MNCs) were collected. After two washes in PBS con-
taining 2% of FBS, the pellet were diluted with CFU-
Hill Liquid medium kit, and these cells were counted 
using hemocytometry. Total mononuclear cells (cell 
density 5x106 cells/ml) were plated on fibronectin 
coated well plates. After two days, nonadherent cells 
were transferred into new fibronectin coated well plates 
for colony counts and MTT cell proliferation assay. 
Statin 
After 24 hours of another incubation, three doses 
of statins, which were 0.1 µmol/L, 0.5 µmol/L, dan 
2.5 µmol/L of simvastatin (Abcam®), atorvastatin 
(Tocris®), and rosuvastatin (Tocris®) were added to 
three different plates. Colony counts and MTT cell 
proliferation assay were determined after 48 hours of 
incubation.
EPC proliferation assay
Effects of statins on EPC proliferation were deter-
mined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay. Each well was 
supplemented with MTT and incubated for a further 
span of 4 hours. Optical density (OD) was measured 
at 595 nm.
Colony counting 
EPC colony was combination of 15 or more EPC, 
which can be round, spindle-shape, or cobblestone-
like shape. All colonies from each fibronectin coated 
well plate were analysed with an inverted light 
microscope.
Immunofluorescence assay
 Cells were washed with PBS and fixed with 3% 
formaldehyde for 15 minutes. Cells then added with 
the blood vessels that results in coronary heart disease 
is known as atherosclerosis.2 Atherosclerotic lesions 
are initiated by endothelial damage which develop 
as the result of an inflammatory process over many 
years then become coronary artery disease.3 Stable 
coronary artery disease is generally characterized by 
a disease causing exercise- and stress-related chest 
symptoms due to narrowing of ≥50% in the left main 
coronary artery and  ≥70% in one or several of the 
major coronary arteries.4  Endothelium has the abil-
ity to repair itself. It is not only driven by local cells, 
but also with the contribution of circulating cells, 
which have been termed endothelial progenitor cells 
(EPCs). EPCs derive from bone marrow and can be 
mobilized to the peripheral circulation upon a vari-
ety of stimuli including tissue ischemia through the 
release of growth factors.3 Experimental and clinical 
studies have shown that atherosclerosis is associated 
with reduced numbers and dysfunction of EPCs, 
and there are various ways to increase circulating 
EPCs and improve their function.5 Cardiovascular 
pharmacotherapies have been shown to improve 
overall numbers and function of EPCs, such as statins, 
angiotensin converting enzyme (ACE) inhibitors, 
calcium channel blockers (CCBs). 
Hydroxymethyl glutaryl coenzyme A (HMG-
CoA) reductase inhibitors, statins, have already led to 
important improvements in primary and secondary 
prevention of coronary artery disease (CAD).6 Besides 
lipid lowering, statins can reduce vascular inflamma-
tion, decrease platelet aggregability and thrombus 
deposition, and increase endothelium-derived nitric 
oxide production.7,8 Moreover, different doses of differ-
ent statins have been reported to be useful in increasing 
EPC numbers and function.9 Here, we need a research 
to analyze the effects of three different statins on EPC 
proliferation.
Methods
Blood samples were taken from patients with stable 
coronary artery disease which were men, 40-59 years 
old, had narrowing of ≥50% in the left main coronary 
artery and ≥70% in one or several of the major coro-
nary arteries from angiography.
Patients with history of acute myocardial infarc-
tion, acute limb ischemia, stent placement, coronary 
artery bypass grafting, diabetes mellitus, smoking, and 
anemia were excluded.
Written informed consent was obtained from pa-
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1% serum and washed again with PBS. Cells were 
stained with a FITC anti-CD34 antibody. Expression 
of the cells was documented with fluorescence 
microscope.
Statistical analysis 
Data are expressed as mean±SD. To analyse differences, 
one-way ANOVA was used. Differences were 
considered significant if p-values were <0.05. All 
statistical analyses were performed with SPSS for 
Windows (IBM Corp., Armonk, NY).
Results
Statin increases EPC proliferation
To investigate the effect of statins on EPC 
proliferation, we added three different types of 
statins on EPC cultures. MTT cell proliferation 
assay of the lowest dose of each statins, which 
was 0.1 µmol/L, showed a significant increase of 
EPC proliferation in simvastatin, atorvastatin, 
and rosuvastatin groups compared with control 
group (0.237±0.007, 0.248±0.01, 0.231±0.008 vs. 
0.17±0.008, p<0.05). It also revealed significant 
difference in EPC proliferation between each 
experiment groups, which atorvastatin showed the 
highest effect. EPC proliferation in atorvastatin 
was higher than simvastatin group (0.248±0.01 vs. 
0.237±0.007, p<0.05), and simvastatin was also 
higher than rosuvastatin group (0.237±0.007 vs. 
0.231±0.008, p<0.05) (Figure 1).
EPC proliferation induced by statins was dose 
dependent. Three different doses of simvastatin, ator-
vastatin and rosuvastatin, which were 0.1 µmol/L, 0.5 
µmol/L, 2.5 µmol/L, respectively, increase EPC prolif-
eration according to the dosage. 2.5 µmol/L rosuvastatin 
expressed the highest EPC proliferation (0.243±0.005 
vs. 0.232±0.003, p<0.05). 0.5 µmol/L rosuvastatin 
showed a non-significant increase of EPC prolif-
eration than 0.1 µmol/L rosuvastatin (0.232±0.003 
vs. 0.231±0.008). 2.5 µmol/L simvastatin showed 
significantly higher EPC proliferation than 0.5 µmol/L 
simvastatin (0.26±0.006 vs. 0.244±0.003, p<0.05), 
and 0.1 µmol/L simvastatin also demonstrated lower 
effect than 0.5 µmol/L simvastatin (0.237±0.007 vs. 
0.244±0.003, p<0.05). Atorvastatin group also showed 
similar results. 2.5 µmol/L atorvastatin significantly 
increased EPC proliferation than 0.5 µmol/L atorvas-
tatin (0.2740±0.005 vs. 0.263±0.004, p<0.05) and 0.1 
µmol/L atorvastatin had the lowest effect (0.248±0.01 
vs. 0.263±0.004, p<0.05) (Figure 2).
CFU counts 
The ability of EPCs to migrate to each other to form 
a colony represents their functional characteristics. We 
observed the EPC on the sixth day of culture to ensure 
they could form colonies (Table 1 and Figure 3).
Immunofluorescence assay
CD34 is one of the positive marker for EPC. After 
CFU counts, one of the well was washed with PBS and 
stained with a FITC anti-CD34 antibody. Expression 
of CD34 was green under fluorescence microscope 
(Figure 4).
Discussions
The results of the present study demonstrate that statin 
significantly increases EPC proliferation in patients 
with stable CAD. There were different effects in EPC 
proliferation induced by each statins. Atorvastatin had 
the highest effect of EPC proliferation, and simvastatin 
could proliferate more EPC than rosuvastatin. 
Many studies have reported the beneficial effects 
of statin on EPCs. Similar to this result, Llevadot, et al. 
reported that simvastatin increased EPC proliferative 
activity using EPC culture assay of peripheral blood 
from simvastatin-treated animals in vivo.10 Vasa, et 
al. demonstrated that atorvastatin 40 mg treatment 
of patients with stable coronary artery disease was 
Figure 1. Statins increase EPC proliferation. EPC prolif-
eration were expressed as optical density (O.D).
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Figure 2. EPC proliferation in experiment groups. (A) Rosuvastatin group (B) 
Atorvastatin group (C) Atorvastatin group. 
Figure 3. CFU in control and experiments group. (A) Control group (B) 
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associated with an 1.5-fold increase in the number of 
circulating EPCs by one week treatment and 3-fold 
throughout the 4-week period.11 Another studies also 
used several types of statins but they did not directly 
compare the results. Spiel, et al. explored the effect of 
statin using simvastatin and rosuvastatin. The results 
showed that five days pre-treatment with 80 mg of 
simvastatin increased EPCs 2.1-fold, whereas pre-
treatment with 40 mg of rosuvastatin led to a 1.9 fold 
increase as compared to baseline values.12 Dimmeler, 
et al. also used three different types of statins, which 
were simvastatin, mevastatin, and atorvastatin. The 
results demonstrated that incubation of isolated hu-
man MNCs with statin increased the number of EPCs. 
Atorvastatin augmented the number of EPCs more 
than simvastatin, and mevastatin had higher number 
of EPCs than atorvastatin.13 
Dimmeler, et al. demonstrated that statins en-
hanced the mobilization of EPCs from bone marrow 
to newly forming blood vessels through the PI3K/Akt 
pathway, which lead to an increase in endothelial nitric 
oxide synthase (eNOS) and nitric oxide (NO) produc-
tion, as NO is essential for EPC proliferation.13,14 The 
mechanism underlying different effect of statins on EPC 
proliferation still needs to be determined. Although all 
statins share a common mechanism of action, they differ 
in terms of their chemical structures, pharmacokinetic 
profiles, and lipid-modifying efficacy. Simvastatin are 
derived from fungal metabolites, but atorvastatin and 
rosuvastatin are fully synthetic compounds. Atorvastatin 
and simvastatin are relatively lipophilic compounds, 
while rosuvastatin are relatively hydrophilic.15 These 
differences might influence the effect on EPC prolifera-
tion induced by different types of statin.
The result of this study also showed that simvas-
tatin, atorvastatin, and rosuvastatin dose dependently 
increased EPC proliferation. Likewise, Dimmeler, et 
al. demonstrated that simvastatin, mevastatin, and 
atorvastatin dose dependently increased the number 
of differentiated EPCs.13   
CFU counts represent the cumulative characteris-
tics of EPC quantity and their functional characteris-
tics, and cannot be reliably used for the estimation of 
EPC numbers in peripheral blood.16 We only examined 
seven wells, which is control group, the low and high 
dose of each simvastatin, atorvastatin, and rosuvastatin. 
The results demonstrated that atorvastatin had the 
most CFU counts, while rosuvastatin had the most 
CFU counts in high dose group. Therefore, rosuvasta-
tin might have another functional capacity better than 
atorvastatin and simvastatin. The amount of CFU also 
showed that it depends on the dose of statins. 
EPCs appear to be a heterogenous group of cells 
originating from multiple precursors within the bone 
marrow and present in different stages of endothelial 
differentiation in peripheral blood. For this reason, the 
precise characterization of EPCs is difficult because 
many of the cell surface markers used in phenotyping 
are shared by hematopoietic stem cells and by adult 
endothelial cells. Currently, EPCs are defined as cells 
positive for both hematopoietic stem cell marker such 
as CD34 and an endothelial marker protein such as 
VEGFR2.9 This study used CFU-Hill Liquid medium 
kit which has been developed specifically to support the 
culture from mononuclear cells of human peripheral 
blood. To ensure the colonies cultured were EPC, we 
used one of the EPC markers, which was CD34 and 
the result came out positive for CD34. 
Conclusion
The results of the present study define that statin 
increases EPC proliferation from peripheral blood of 









Figure 4. Immunofluorescence expression of CD34.
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stable coronary artery disease patient. Our data suggests 
that atorvastatin has the highest EPC proliferation, 
followed by simvastatin, and rosuvastatin. Each statin 
increases EPC proliferation dose-dependently. 
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